Drug intelligence / Profile preview

aristolochic acid I

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral
01

Overview

Aristolochic acid I is a **naturally occurring nitrophenanthrene carboxylic acid** and the most abundant member of the aristolochic acids found in herbs of the Aristolochiaceae family, such as Aristolochia and Asarum[1][4]. It is a **highly carcinogenic, mutagenic, and nephrotoxic phytochemical**, historically present in herbal remedies, especially traditional Chinese medicine[1]. AA-I is absorbed orally, distributed systemically, and primarily metabolized by phase I nitroreduction to aristolactam I, which forms **stable DNA adducts** leading to A→T transversion mutations and selective TP53 tumor suppressor gene mutations[1][3][5]. It acts as a **phospholipase A2 inhibitor** and is bioactivated to reactive N-acylnitrenium ions that alkylate DNA, driving its mutagenic and carcinogenic effects[3][5]. AA-I has been definitively linked to urothelial malignancy, kidney failure, and aristolochic acid nephropathy (AAN)[1][5]. It is not approved for any pharmaceutical indication and is considered a toxin, not a therapeutic drug.

Other names
8-methoxy-6-nitrophenanthrol(3,4-d)-1,3-dioxide-5-carboxylic acidAristolochic acid AAristolochic acid I methyl ester (used for the methylated derivative)Aristolochic acid-IAristolochic acids (occasionally, but refers to a mixture)Birthwort (traditional/herbal reference)
02

Targets

CYP1A1 (Cytochrome P450 1A1)PLA2 (Phospholipase A2 group IID)DNACYP1A2 (Cytochrome P450 1A2)NQO1

Beyond the preview

Go deeper on aristolochic acid I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aristolochic acid I.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call